WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H563376
CAS#: 139689-19-3
Description: R(+)-6-Bromo-APB HBr is a potent D1 Dopamine receptor agonist.
Hodoodo Cat#: H563376
Name: R(+)-6-Bromo-APB HBr
CAS#: 139689-19-3
Chemical Formula: C19H21Br2NO2
Exact Mass: 0.00
Molecular Weight: 455.190
Elemental Analysis: C, 50.13; H, 4.65; Br, 35.11; N, 3.08; O, 7.03
Synonym: R(+)-6-Bromo-APB hydrobromide; R(+) 6 Bromo APB hydrobromide; R(+)-6-Bromo-APB HBr; R(+) 6 Bromo APB HBr;
IUPAC/Chemical Name: (R)-3-allyl-6-bromo-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol hydrobromide
InChi Key: CTAUBYSSTAODOD-PKLMIRHRSA-N
InChi Code: InChI=1S/C19H20BrNO2.BrH/c1-2-9-21-10-8-14-15(11-17(22)19(23)18(14)20)16(12-21)13-6-4-3-5-7-13;/h2-7,11,16,22-23H,1,8-10,12H2;1H/t16-;/m1./s1
SMILES Code: OC1=C(O)C=C2[C@@H](C3=CC=CC=C3)CN(CC=C)CCC2=C1Br.Br
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 455.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Navakkode S, Sajikumar S, Frey JU. Synergistic requirements for the induction of dopaminergic D1/D5-receptor-mediated LTP in hippocampal slices of rat CA1 in vitro. Neuropharmacology. 2007 Jun;52(7):1547-54. Epub 2007 Mar 12. PubMed PMID: 17433377.
2: Mockett BG, Brooks WM, Tate WP, Abraham WC. Dopamine D1/D5 receptor activation fails to initiate an activity-independent late-phase LTP in rat hippocampus. Brain Res. 2004 Sep 17;1021(1):92-100. PubMed PMID: 15328036.
3: Azaryan AV, Clock BJ, Rosenberger JG, Cox BM. Transient upregulation of mu opioid receptor mRNA levels in nucleus accumbens during chronic cocaine administration. Can J Physiol Pharmacol. 1998 Mar;76(3):278-83. PubMed PMID: 9673791.
4: Sun MH, Ishine T, Lee TJ. Dopamine constricts porcine pial veins. Eur J Pharmacol. 1997 Sep 10;334(2-3):165-71. PubMed PMID: 9369345.
5: Azaryan AV, Clock BJ, Cox BM. Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem Res. 1996 Nov;21(11):1411-5. PubMed PMID: 8947931.